Needham analyst Alan Carr assigned a Buy rating to Alnylam Pharma (ALNY) today and set a price target of $160.00. The company’s shares closed last Thursday at $142.39.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 0.8% and a 41.2% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $160.64, which is an 8.1% upside from current levels. In a report issued on July 29, Jefferies also maintained a Buy rating on the stock with a $179.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $167.33 and a one-year low of $72.67. Currently, Alnylam Pharma has an average volume of 768.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Read More on ALNY:
